

Hui-Chu Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8503744/publications.pdf>

Version: 2024-02-01

25
papers

482
citations

687363

13
h-index

713466

21
g-index

25
all docs

25
docs citations

25
times ranked

849
citing authors

#	ARTICLE	IF	CITATIONS
1	Statins decrease the risk of decompensation in hepatitis B virus-related and hepatitis C virus-related cirrhosis: A population-based study. <i>Hepatology</i> , 2017, 66, 896-907.	7.3	89
2	Validation of EQ-5D in patients with cervical cancer in Taiwan. <i>Supportive Care in Cancer</i> , 2010, 18, 1279-1286.	2.2	46
3	Willingness to Pay for Lung Cancer Treatment. <i>Value in Health</i> , 2010, 13, 743-749.	0.3	42
4	Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. <i>Acta Cardiologica Sinica</i> , 2017, 33, 10-19.	0.2	30
5	Impact of the case payment reimbursement method on the utilization and costs of laparoscopic cholecystectomy. <i>Health Policy</i> , 2004, 67, 195-206.	3.0	28
6	Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 9-19.	1.9	28
7	The Lifetime Cost of Hepatocellular Carcinoma. <i>Applied Health Economics and Health Policy</i> , 2008, 6, 55-65.	2.1	23
8	The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. <i>Journal of Medical Economics</i> , 2016, 19, 923-927.	2.1	23
9	Lifetime costs of the top five cancers in Taiwan. <i>European Journal of Health Economics</i> , 2012, 13, 347-353.	2.8	22
10	QUALITY OF LIFE, TREATMENTS, AND PATIENTS' WILLINGNESS TO PAY FOR A COMPLETE REMISSION OF CERVICAL CANCER IN TAIWAN. <i>Health Economics (United Kingdom)</i> , 2012, 21, 1217-1233.	1.7	22
11	Risk of major depression in patients with chronic renal failure on different treatment modalities: A matched-cohort and population-based study in Taiwan. <i>Hemodialysis International</i> , 2016, 20, 98-105.	0.9	21
12	The Cost of Schizophrenia Treatment in Taiwan. <i>Psychiatric Services</i> , 2004, 55, 928-930.	2.0	18
13	Evaluating the Operational Efficiency and Quality of Tertiary Hospitals in Taiwan: The Application of the EBITDA Indicator to the DEA Method and TOBIT Regression. <i>Healthcare (Switzerland)</i> , 2022, 10, 58.	2.0	15
14	Willingness to pay to sustain and expand National Health Insurance services in Taiwan. <i>BMC Health Services Research</i> , 2008, 8, 261.	2.2	13
15	The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003: A global pharmaceutical data analysis. <i>Health Policy</i> , 2010, 97, 71-78.	3.0	13
16	Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease: A five-year follow-up study. <i>Health Policy</i> , 2019, 123, 229-234.	3.0	9
17	Outpatient drug expenditures and prescription policies for diseases with high cost to the National Health Insurance system in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2004, 103, 280-5.	1.7	6
18	Evaluating the comparative efficiency of medical centers in Taiwan: a dynamic data envelopment analysis application. <i>BMC Health Services Research</i> , 2022, 22, 435.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Effects of hospital generic drug substitution on diabetes therapy. Patient Preference and Adherence, 2014, 8, 127.	1.8	5
20	The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study. International Journal of Rheumatic Diseases, 2016, 19, 1112-1118.	1.9	5
21	Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. Hepatology International, 2018, 12, 531-543.	4.2	5
22	Potentially preventable hospital readmissions after patients' first stroke in Taiwan. Scientific Reports, 2022, 12, 3743.	3.3	5
23	Association between continuity of care and long-term mortality in Taiwanese first-ever stroke survivors: An 8-year cohort study. PLoS ONE, 2019, 14, e0216495.	2.5	4
24	Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 489-495.	1.4	3
25	Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncology, 2022, , .	2.4	1